E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1, Pharmaceuticals Industry Research Report -MRH

According to the recently published report 'E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2017'; E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 27 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177487

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

The report “E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review H1 2017” outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Lymphoma, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Glioblastoma Multiforme (GBM), Osteosarcoma, Refractory Multiple Myeloma, Bone Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Follicular Lymphoma, Hematological Tumor, Leukemias, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Peripheral T-Cell Lymphomas (PTCL), Proliferative Vitreoretinopathy (PVR), Relapsed Multiple Myeloma, Retinoblastoma, Soft Tissue Sarcoma, Uveal Melanoma and Well Differentiated Liposarcoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Browse Full Report With TOC @ http://www.marketresearchhub.com/report/e3-ubiquitin-protein-ligase-mdm2-double-minute-2-protein-or-hdm2-or-oncoprotein-mdm2-or-p53-binding-protein-mdm2-or-mdm2-or-ec-632-pipeline-review-h1-2017-report.html

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1177487

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/

This release was published on openPR.